se tirzepatide more effective in blood sugar control and weight loss than semaglutide, meta-analysis finds Zepbound now available in multi-dose

The authors thank the participants, the investigators, all trial site staff and all Novo Nordisk A/S employees involved in the trial

Research Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial Deanfield J., Lincoff A.M., Kahn S.E., et al

Suppresses appetite by acting on the brains hunger centers

Understanding the Study Timeline: Phase 2a vs Phase 3 Phase 2a MASLD Substudy (2023) - SOURCE OF 86% RESOLUTION DATA Status: COMPLETED and published Study Design: Part of larger Phase 2 obesity trial (NEJM 2023) Focused substudy on patients with MASLD Liver fat measured by MRI-PDFF (gold standard) Duration: 48 weeks Published results available This is where the 82.4% liver fat reduction and 86% resolution rate data comes from

Interleukin-17/interleukin-17 receptor axis elicits intestinal neutrophil migration, restrains gut dysbiosis and lipopolysaccharide translocation in high-fat diet-induced metabolic syndrome model